Description

Letrovista Coated Tablets 2.5 mg. № 30

Ingredients

Letrozole – 2.5 mg per tablet, lactose monohydrate, maize starch, povidone, sodium starch glycolate, magnesium stearate, hypromellose, macrogol 6000, titanium dioxide (E171).

Dosage

The recommended dosage of Letrovista coated tablets is 2.5 mg once daily, with or without food, or as directed by a healthcare professional.

Indications

Letrovista tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Contraindications

Do not use Letrovista tablets if you are pregnant, breastfeeding, or allergic to letrozole or any other ingredients in the product.

Directions

Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. Follow the dosage instructions provided by your healthcare provider.

Scientific Evidence

Letrovista (letrozole) has been extensively studied in clinical trials for its efficacy in the treatment of hormone receptor-positive breast cancer. Research has shown that letrozole is a potent aromatase inhibitor, effectively reducing estrogen levels in postmenopausal women, thereby inhibiting the growth of hormone-sensitive tumors.

Clinical trials have demonstrated the superiority of letrozole over tamoxifen in terms of disease-free survival and overall survival in postmenopausal women with early breast cancer. Letrozole has become a standard adjuvant treatment option due to its proven efficacy and tolerability profile.

Additional Information

It is important to notify your healthcare provider about any other medications you are taking before starting Letrovista tablets to prevent potential drug interactions. Common side effects may include hot flashes, fatigue, and joint pain.

Always consult your doctor for personalized medical advice and follow-up while taking Letrovista tablets to ensure optimal treatment outcomes and monitoring of any potential side effects.